The acquisition includes Valencia, Calif.-based Bioness’ six-device portfolio of peripheral nerve stimulation therapy technology sold in 40 countries worldwide, according to a March 31 release.
Bioness systems are designed to help patients regain mobility after a stroke, traumatic brain injury, multiple sclerosis and osteoarthritis.
The total addressable market for Bioness medical devices is estimated to be more than $8 billion. In 2020, Bioness generated approximately $40 million in revenue.
More articles on devices:
Spinal fusion ‘picking up steam’ at ASCs: 2 leaders discuss practice growth
Alphatec, NuVasive & SeaSpine: Key spine acquisitions in 2021
Why endoscopic spine surgery in the US lags behind Europe, Asia
